Evidence map›Paper›PMID 41521331›Full record

ArticleJournal of translational medicine2026

Triple-remodeling of tumor microenvironment through hyaluronidase-assisted folate-targeted lipid nanoparticle-mediated siVEGF/siPD-L1 for enhanced tumor immunotherapy.

Xin Li, Haowen Xue, Qingping Liu, Luquan Ren, Yu Sun

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin LiOrthopaedic Medical Center, The 2nd Hospital of Jilin University, Changchun, 130041, China.
Haowen XueOrthopaedic Medical Center, The 2nd Hospital of Jilin University, Changchun, 130041, China.
Qingping LiuKey of Bionic Engineering, Ministry of Education, Jilin University, Changchun, 130022, China.
Luquan RenKey of Bionic Engineering, Ministry of Education, Jilin University, Changchun, 130022, China.
Yu SunOrthopaedic Medical Center, The 2nd Hospital of Jilin University, Changchun, 130041, China. yusun@jlu.edu.cn.

Funding

Health Commission of Jilin Province 2020SC2T062
6 · The paper itself

Abstract

backgroundIn tumor therapy, traditional single-treatment methods often fail to achieve ideal results because of problems like the complex tumor microenvironment, immune escape mechanisms, and abnormal blood vessel formation. Although there are now several combined treatment strategies, challenges remain in precise drug delivery and achieving multi - target synergistic effects.

methodsThis study aims to create an efficient combined anti-tumor lipid nanoparticle (LNP) delivery system. We added DMG-PEG2000-FA to the four-component lipid nanoparticle system and used microfluidic technology to prepare FA-LNP with tumor-targeting groups. These delivery systems were loaded with the pSpam-1 gene, siVEGF, and siPD-L1 separately.

resultsThe pSpam-1 gene can express hyaluronidase in tumor tissues, degrade the tumor extracellular matrix, and boost the infiltration of nanodrugs and immune cells into tumor tissues. siVEGF exerts an anti-angiogenic effect, cutting off tumor nutrient supply. siPD-L1 achieves immune checkpoint blockade, activating the body’s immune system. Experimental show that this FA-LNP achieves effective multi-target synergy, greatly inhibiting tumor growth and achieving highly efficient combined anti-tumor effects both in vitro and in vivo. Further immune mechanism research reveals it can regulate immune cell function and distribution in the tumor microenvironment.

conclusionsCombining extracellular matrix degradation, anti-angiogenesis, and immune checkpoint blockade led to a highly efficient synergistic anti-tumor effect. The in-depth immune mechanism research offers valuable insights into how these strategies interact and contribute to the overall anti-tumor response. This FA-LNP delivery system is expected to offer a safer and more effective tumor therapy strategy and promote personalized tumor treatment development.

Indexed as

B7-H1 AntigenFolic AcidHyaluronoglucosaminidaseImmunotherapyLipidsNanoparticlesNeoplasmsRNA, Small InterferingTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansMice, Inbred BALB CNeovascularization, PathologicB7-H1 AntigenFolic AcidHyaluronoglucosaminidaseLipidsRNA, Small InterferingAnti-angiogenicExtracellular matrixGene silencingImmune checkpoint blockadeTarget lipid nanoparticles

Identifiers

PMID41521331
PMCPMC12797798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.